73620-18-5

Usage

Uses

Used in Pharmaceutical Industry:
Methyl (4-formylphenoxy)acetate is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs and bioactive molecules.
Used in Agrochemical Industry:
In the agrochemical sector, methyl (4-formylphenoxy)acetate is employed as an intermediate in the production of various agrochemicals, playing a crucial role in the synthesis of compounds that aid in crop protection and enhancement.
Used in Organic Chemistry Research:
Methyl (4-formylphenoxy)acetate serves as a valuable compound in organic chemistry research, where it is used for the exploration and creation of novel drug candidates and other bioactive molecules, contributing to scientific advancements in the field.

InChI:InChI=1/C10H10O4/c1-13-10(12)7-14-9-4-2-8(6-11)3-5-9/h2-6H,7H2,1H3

Upstream product

• 67-56-1 methanol 
• 22042-71-3 (4-formylphenoxy)acetic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 96-35-5 glycolic acid methyl ester 
• 123-08-0 4-hydroxy-benzaldehyde 
• 96-32-2 bromoacetic acid methyl ester 
• 96-34-4 methyl chloroacetate 
• 186581-53-3 diazomethane 

Downstream Products

• 1123756-74-0 (E,Z)-methyl 2-{4-[(2,4-dioxodihydrofuran-3(2H)-ylidene)methyl]phenoxy}acetate 
• 1310696-59-3 Methyl [4-({[({3-[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]propyl}amino)carbonyl][3-(dimethylamino)propyl]amino}methyl)phenoxy]acetate 
• 1310696-60-6 Methyl [4-({[3-(dimethylamino)propyl]amino}methyl)phenoxy]acetate 
• 1387473-11-1 C₃₁H₃₁F₂NO₆S 
• 1369489-34-8 C₃₆H₃₉F₂N₃O₇S 
• 1369489-40-6 C₁₀H₁₇N*C₂₅H₂₁F₂NO₅S 
• 1448677-84-6 3-((Z)-((Z)-5-(4-(2-methoxy-2-oxoethoxy)benzylidene)-3-ethyl-4-oxothiazolidin-2-ylidene)amino)benzoic acid 
• 1448677-93-7 C₂₃H₂₂N₂O₆S 
• 1448677-99-3 methyl 2-(4-((Z)-((Z)-2-((3-acetylphenyl)imino)-3-ethyl-4-oxothiazolidin-5-ylidene)methyl)phenoxy)acetate 
• 1448677-87-9 C₂₃H₂₂N₂O₆S 
• 1448678-05-4 C₂₄H₂₂N₂O₅S 

Relevant academic research and scientific papers

Synthesis and antileukemic activity of 16E-[4-(2-carboxy)ethoxybenzylidene] -androstene amides

In order to determine the structural requirements for cytotoxicity against various tumor cell lines, a new series of 16E-arylidene androstene amides with varying degrees of unsaturation in ring A has been synthesized. Characterization and in vitro cytotox

Phosphatase Binding Compounds and Methods of Using Same

The present invention provides bifunctional compounds that efficiently dephosphorylate certain phospho-activated target proteins. Such target proteins can be any protein involved in the pathway of a disease or disorder, such as but not limited to cancer, neurodegeneration, metabolic disease, diabetes, insulin resistance, and so forth.

INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR PROMOTING NEUROGENESIS AND INHIBITING NERVE CELL DEATH

A method of promoting neuroprotection in a subject from axonal degeneration, neuronal cell death, and/or glia cell damage after injury, augmenting neuronal signaling underlying learning and memory, stimulating neuronal regeneration after injury, and/or treating a disease, disorder, and/or condition of the nervous system in a subject in need thereof includes administering to the subject a therapeutically effective amount of a 15-PGDH inhibitor.

Boosting Self-Assembly Diversity in the Solid-State by Chiral/Non-Chiral ZnII-Porphyrin Crystallization

A chiral ZnII porphyrin derivative 1 and its achiral analogue 2 were studied in the solid state. Considering the rich molecular recognition of designed metalloporphyrins 1 and 2 and their tendency to crystallize, they were recrystallized from t

Synthesis and pharmacological characterization of novel xanthine carboxylate amides as A2A adenosine receptor ligands exhibiting bronchospasmolytic activity

The carboxylate amides of 8-phenyl-1,3-dimethylxanthine described herein represent a new series of selective ligands of the adenosine A2A receptors exhibiting bronchospasmolytic activity. The effects of location of 8-phenyl substitutions on the

INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR TREATING FIBROSIS

A method of treating or preventing a fibrotic disease, disorder or condition includes administering to a subject in need of treatment a 15-PGDH inhibitor.

A process for the preparation of intermediates palestinian multi-past fragrance acetate

The invention discloses a method for preparing a bazedoxifene acetate intermediate. The preparation method comprises the following steps: 1, condensing 4-hydroxybenzaldehyde S01 and alkylate S02 to prepare a 4-formyl phenoxy derivative M01; 2, performing

COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY

Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH inhibitors described herein.

Selection and development of a route for cholesterol absorption inhibitor AZD4121

The development of a synthetic route to the cholesterol absorption inhibitor AZD4121 is presented. Key steps are a highly enantioselective CBS reduction, a stereospecific Staudinger reaction, an amine/lithium chloride mediated ester hydrolysis, and a resolution of a 50:50 diastereomeric mixture by recrystallization. The synthesis was accomplished in 10 linear steps, and the overall yield, when compared with the lead optimization (LO) route, was improved from 1% to 20%. All purifications of intermediates through preparative HPLC or silica gel chromatography were avoided. This was possible since many of the intermediates along the route could be used as such in the next step until an intermediate with suitable crystalline properties could be identified and purified through crystallization.

Novel Compounds

The present invention provides compounds of formula (I): wherein Ra, Rb, Rc, R1, R2, R3, X1, Y1, Z1, A, n and m are as defined in the specification, and pharmaceutically acceptable salts thereof, as well as processes for their preparation, pharmaceutical compositions containing them and their use in therapy.